{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:23:06Z","timestamp":1788308586823,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Reference Network RITA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Immune checkpoint inhibitors (ICI), i.e., anti-PD1\/PDL1 and anti-CTLA-4, have reshaped the prognosis of many cancers. Increased use of ICI has led to the onset of new adverse events. Neurological immune-related adverse events are rare, heterogenous, and potentially life-threatening. Chronic intestinal pseudo-obstruction (CIPO) is an immune-related autonomic plexus neuropathy that may be caused by infiltration of the myenteric plexus by CD8\u2009+\u2009T cells. It is a rare and potentially fatal side effect that can be difficult to diagnose early because of initial nonspecific clinical presentation including vomiting, nausea, diarrhea, and constipation. Some rare cases have been described in the literature reporting a frequent resistance to corticosteroids making it necessary to use other immunosuppressive therapy. Vedolizumab is an antibody (Ab) blocking integrin \u03b14-\u03b27 used to treat inflammatory bowel disease. We report the first three cases of ICI-induced CIPO-treated with vedolizumab after corticosteroid failure, with very limited benefits (only one patient with transitory improvement). Based on our results in three cases, vedolizumab does not currently appear to be a therapeutic option. Earlier administration with a standardized dose and frequency schedule may provide better outcomes.<\/jats:p>","DOI":"10.1007\/s00262-024-03901-4","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:49:08Z","timestamp":1735897748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-PD1-\/PDL1-induced chronic intestinal pseudo-obstruction: three cases treated with vedolizumab after corticosteroid failure with mixed results"],"prefix":"10.1007","volume":"74","author":[{"given":"Morgan","family":"Zenatri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifanie","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Collardeau-Frachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Saint-Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bocquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Raimbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"19","key":"3901_CR1","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.3748\/wjg.14.2953","volume":"14","author":"A Antonucci","year":"2008","unstructured":"Antonucci A, Fronzoni L, Cogliandro L, Cogliandro RF, Caputo C, De Giorgio R et al (2008) Chronic intestinal pseudo-obstruction. World J Gastroenterol 14(19):2953\u201361","journal-title":"World J Gastroenterol"},{"issue":"3","key":"3901_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MOG.0000000000000630","volume":"36","author":"L Zenzeri","year":"2020","unstructured":"Zenzeri L, Tambucci R, Quitadamo P, Giorgio V, De Giorgio R, Di Nardo G (2020) Update on chronic intestinal pseudo-obstruction. Curr Opin Gastroenterol 36(3):230\u2013237","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"3901_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/MCG.0000000000001047","volume":"52","author":"TJ Downes","year":"2018","unstructured":"Downes TJ, Cheruvu MS, Karunaratne TB, De Giorgio R, Farmer AD (2018) Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol 52(6):477\u2013489","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"3901_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B (2016) an overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 10(12):1437\u20131444","journal-title":"J Crohns Colitis"},{"issue":"5","key":"3901_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S et al (2017) Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother CII 66(5):581\u2013592","journal-title":"Cancer Immunol Immunother CII"},{"issue":"1","key":"3901_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R et al (2024) Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23(1):81\u201394","journal-title":"Lancet Neurol"},{"issue":"2","key":"3901_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1078155217738325","volume":"25","author":"G Fragulidis","year":"2019","unstructured":"Fragulidis G, Pantiora E, Michalaki V, Kontis E, Primetis E, Vezakis A et al (2019) Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 25(2):487\u201391","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"1","key":"3901_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","volume":"6","author":"J Appelbaum","year":"2018","unstructured":"Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H et al (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6(1):82","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3901_CR9","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","volume":"28","author":"M Collins","year":"2017","unstructured":"Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C et al (2017) Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol Off J Eur Soc Med Oncol 28(11):2860\u20135","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"3901_CR10","doi-asserted-by":"publisher","first-page":"e232388","DOI":"10.1136\/bcr-2019-232388","volume":"12","author":"RJ Besaw","year":"2019","unstructured":"Besaw RJ, Smith MP, Zerillo JA, Bullock AJ (2019) Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab. BMJ Case Rep 12(12):e232388","journal-title":"BMJ Case Rep"},{"issue":"13","key":"3901_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2217\/imt-2020-0350","volume":"13","author":"IP Trontzas","year":"2021","unstructured":"Trontzas IP, Rapti VE, Syrigos NK, Kounadis G, Perlepe N, Kotteas EA et al (2021) Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer. Immunotherapy 13(13):1085\u20131092","journal-title":"Immunotherapy"},{"key":"3901_CR12","first-page":"100014","volume":"1","author":"S Andrews","year":"2020","unstructured":"Andrews S, Ludlow SP (2020) Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer. Curr Probl Cancer Case Rep 1:100014","journal-title":"Curr Probl Cancer Case Rep"},{"issue":"6","key":"3901_CR13","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.14309\/crj.0000000000000105","volume":"6","author":"JA Cerra-Franco","year":"2019","unstructured":"Cerra-Franco JA, Fernandez-Cruz C, Estremera-Marcial R, Pagan-Torres H, Martinez-Souss J, Toro DH (2019) Anti-hu-mediated paraneoplastic chronic intestinal pseudo-obstruction arising from small cell prostate cancer. ACG Case Rep J 6(6):e00105","journal-title":"ACG Case Rep J"},{"issue":"5","key":"3901_CR14","doi-asserted-by":"publisher","first-page":"fcad247","DOI":"10.1093\/braincomms\/fcad247","volume":"5","author":"M Villagr\u00e1n-Garc\u00eda","year":"2023","unstructured":"Villagr\u00e1n-Garc\u00eda M, Farina A, Mu\u00f1iz-Castrillo S, Wucher V, Dhairi M, Timestit N et al (2023) Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis. Brain Commun 5(5):fcad247","journal-title":"Brain Commun"},{"issue":"12","key":"3901_CR15","doi-asserted-by":"publisher","first-page":"300060520974466","DOI":"10.1177\/0300060520974466","volume":"48","author":"J Yan","year":"2020","unstructured":"Yan J, Chen Z, Liang Y, Yang H, Cao L, Zhou Y et al (2020) Anti-CV2\/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review. J Int Med Res 48(12):300060520974466","journal-title":"J Int Med Res"},{"issue":"12","key":"3901_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238","journal-title":"Ann Oncol"},{"issue":"11","key":"3901_CR17","doi-asserted-by":"publisher","first-page":"e003277","DOI":"10.1136\/jitc-2021-003277","volume":"9","author":"F Zou","year":"2021","unstructured":"Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X et al (2021) Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11):e003277","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3901_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/apt.15998","volume":"52","author":"H Ibraheim","year":"2020","unstructured":"Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ et al (2020) Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 52(9):1432\u20131452","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3901_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1056\/NEJMc1912274","volume":"382","author":"P Apostolova","year":"2020","unstructured":"Apostolova P, Unger S, Von Bubnoff D, Meiss F, Becher B, Zeiser R (2020) Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy. N Engl J Med 382(3):294\u20136","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03901-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03901-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03901-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T01:10:04Z","timestamp":1739149804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03901-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03901-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0, ,  and .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"45"}}